MedTrace Logo

A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)

NCT03062943 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-09-28

No results posted yet for this study

Summary

This trial is conducted locally. The aim of this trial is assess the efficacy and a favorable benefit-risk ratio for nintedanib in the treatment of LAM at the dose of 150 mg bid

Conditions

  • Lymphangioleiomyomatosis

Interventions

DRUG

Nintedanib

Sponsors & Collaborators

  • IRCCS Multimedica

    lead OTHER

Principal Investigators

  • Sergio A Harari, MD · MultiMedica - San Giuseppe Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-06
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03062943 on ClinicalTrials.gov